FGF/FGFR INHIBITORS HAMPER THE GROWTH OF C-MYC-DRIVEN AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA (SIE 2026) - Oct 6, 2026 - Abstract #SP062; "To note, NSC12 or Erdafitinib showed synergistic effects with the standard therapy R-CHOP. Conclusions. These findings demonstrate that the FGF/FGFR system sustains growth and survival of DLBCL and BL cells and open new therapeutic hints for the treat- ment of c-MYC-driven aggressive B-NHL."
B Cell Non-Hodgkin Lymphoma • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma • ANXA5 • MYC
|
|
J. Faletti1; G. Gazzaroli1; G. Garattini1; R. Ronca1; T. Annese2; R. Castelli3; L. Lorenzi1; A. Tucci4; F. Facchetti1; A. Giacomini1
|